Related Experiment Video
Updated: Feb 10, 2026

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb
Published on: September 23, 2018
Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration
Keyur Patel1, John G McHutchison
1Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P.O. Box 17969, Durham, NC 27715, USA.
Abstract:
The main treatment goal in patients with chronic hepatitis C virus (HCV) infection is the prevention of progressive hepatic fibrosis by eradicating serum and intrahepatic virus. The current standard of care in previously untreated patients with chronic hepatitis C is combination therapy with pegylated interferon alfa and ribavirin. The duration of therapy and the dose of ribavirin should be determined according to the patient's HCV genotype. Adherence to the full dose of therapy for the prescribed treatment duration enhances the likelihood of sustained virologic response. Early virologic response is a good predictor of eventual sustained response for patients with HCV genotype 1 infection. Despite important gains in treating chronic hepatitis C, many treatment challenges remain.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
Initiation of Translation
Gene Therapy
Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...

